Stem Cell Use:
Embryonic Stem Cell
The derivation and culture of human embryonic stem cells has provided new possibilities for treatment of a wide variety of human diseases because these cells have the potential to help regenerate and repair many types of damaged tissue. Diseases for which such cell-based treatments may be helpful include obstructive renal disease, a disorder for which there has been little progress made in terms of treatment. Infants with this and other inherited kidney disease may be severely compromised before birth and treatments necessary to prolong their life may be accompanied by severe side effects. This raises many difficulties not only for these young patients but also for their families. If new ways to treat these infants prior to birth can be developed, this could lead to the delivery of healthy babies at full term. The use of cells obtained from human embryonic stem cells to repair and treat damaged kidneys prior to birth offers promise to improve survival and quality of life for these babies. Since it is clear that embryonic stem cells have vast potential to form a variety of cell types, it is possible that the kinds of cells needed to provide repair could be obtained and treatments initiated prior to birth. The studies proposed will assess ways to obtain such cells and the effectiveness of such treatments. Ultimately, even small improvements in function of damaged kidneys following embryonic stem cell-based therapies may increase survival and eliminate the need for dialysis or kidney transplants. Although methods to grow embryonic stem cells and even obtain cells that could be useful for treating some human diseases have been described, the use of these cells for human therapies remains highly controversial because their safety remains untested. While these cells have great potential and promise to form cell types useful for treatment of disease, they also have the potential for uncontrolled growth and to form tissues that would be harmful. Therefore, studies must be performed and techniques must be developed to carefully examine the use of these cells in relevant models of human disease, and before they are ever considered for human treatments. The overall intent of these studies is to develop techniques that can be used to test the safety of human embryonic stem cell-based therapies, and to determine ways to evaluate the cells after they have been injected into the body. As we develop new treatments for obstructive kidney disease, we will use this model system to explore these essential safety questions related to stem cell therapies. The studies proposed will fill a critical need for new treatments for kidney disease, ways to monitor cells in patients, and develop methods to assess safety issues associated with the transfer of this research to human patients.
Statement of Benefit to California:
This proposal focuses on ways to fill the significant gap in the development of new human therapies using stem cells – transfer of ideas and techniques that are developed in laboratories to effective and safe treatments for human patients afflicted with disease. While the potential medical benefits of human embryonic stem cells may seem great, proof that these cells will not cause harm must be shown, and this must be accomplished before any patients receive treatments. Removing the barrier preventing the transfer of promising stem cell therapies to human patients will require connecting people with the expertise to develop and to evaluate such treatments. With this in mind, our studies will bring together collaborators from many areas: developmental biologists, clinicians, engineers, and those with vast experience in the study of stem cells and with preclinical models to address questions associated with a pediatric kidney disease, which is one of the leading causes of chronic renal failure in children. Kidney disease is a major cause of illness and death among infants and children with over 20,000 babies born each year with kidney problems. Approximately 5,000 have kidney failure and are on dialysis or are in need of a kidney transplant. In California alone, nearly 100 children under 10 years of age are currently awaiting available kidneys for organ transplant. The benefit to the California community is, thus, potential new therapies for the treatment of kidney disease in children, and a model system available to all researchers in which safety and efficacy of embryonic stem cell therapies can be predicted.
We have made substantial progress towards increasing our knowledge about early kidney development, identified new ways to differentiate human embryonic stem cells (hESC) to kidney lineages, and explored the use of these and other related kidney cells to study repopulation of the kidney. In order to obtain the necessary cell types for regenerative medicine purposes, differentiation of hESC must follow developmental pathways and recapitulate normal development, and our studies have brought us closer to this goal. Investigations have supported that expression of early developmental markers provides a useful and efficient method to direct differentiation of hESC towards renal lineages. The results of these studies have established cell culture conditions that ensure we can consistently obtain the quantity of differentiated hESC needed for transplantation into developing and damaged kidneys. Significant progress has also been made in developing new and effective techniques for labeling cells for in vivo imaging, and monitoring the labeled cells post-transplantation using positron emission tomography (PET). We have collected sufficient quantities of cells in culture, and identified effective methods to label the cells without altering viability, proliferation, or function. We have also shown that these same cell populations can be used for transplantation into developing kidneys, and that the cells persist post-transplant over time and can be identified using PET. This strategy has allowed us to precisely document cell location post-transplantation in vivo, demonstrated that post-transplant viability was maintained, and shown that the cells did not migrate to other anatomical sites.
We continue to make substantial progress towards increasing our knowledge about early kidney development and disease, and kidney regeneration strategies, and have successfully applied our methods to differentiate human embryonic stem cells (hESC) to kidney lineages for transplant purposes. We have also accomplished effective radiolabeling of the cells for monitoring post-transplantation, and explored the use of in vivo imaging to monitor the cells.
These studies focus on kidney development and disease, and new cell-based strategies to regenerate damaged kidneys. We have used human embryonic stem cells (hESC) differentiated towards kidney lineages for transplant purposes and monitored these transplanted cells with positron emission tomography (PET) and other related imaging modalities.
The U.S. Renal Data System has reported that the rate of pediatric end stage renal disease has tripled since 1980. Congenital anomalies of the kidney are responsible for the majority of chronic renal failure and end stage disease in young children, with congenital obstruction of the urinary tract the most common. These studies are driven by the fact that the clinical condition of congenital urinary tract obstruction is one of the most important problems affecting young children with kidney disease, and with few therapeutic options. In humans, alterations in the events associated with normal kidney development leads to aberrant kidney structure and postnatally to abnormal kidney function. Little is known about the early cell populations of the developing kidney, thus further understanding of developmental processes is essential to guide regenerative approaches that will ultimately be successful. These studies have focused on several key issues such as understanding developmental timelines for key kidney markers, cell populations, and the interactive molecular and cellular milieu during ontogeny; new explant models to aid in developing the techniques necessary to enhance regeneration of kidneys damaged by obstructive renal disease; explant culture conditions using human embryonic stem cells differentiated towards early renal precursors; effective methods for labeling these cells for in vivo imaging in order to monitor engraftment and outcomes post-transplant; and effective methods to transplant renal precursors within a natural framework into defined anatomical locations of the kidney.